MedPath

Evaluation of the Diagnostic Contribution of High-throughput Exome Sequencing for Patients With Convulsive Encephalopathy of Unknown Etiology: Pilot Study to Improve Genetic Counselling

Completed
Conditions
Epileptic Encephalopathy of Unindentified Genetic Origin
Registration Number
NCT03652246
Lead Sponsor
Centre Hospitalier Universitaire Dijon
Brief Summary

Congenital epileptic encephalopathies (EE) are predominantly genetic in origin. Their diagnosis is hampered by the large number of genes involved and their low recurrence. Genetic study in routine diagnosis is limited by the existing techniques and the development costs. The routine diagnostic implementation of high throughput sequencing pushes these limits. High throughput exome sequencing (ES) showed superior diagnostic performance in all diagnostic settings studied.

This pilot study is dedicated to evaluating the diagnostic performance of high throughput ES in EE, with an implementation and analysis strategy allowing for a direct transfer to routine diagnostics. This novel approach should improve the diagnostic rate while reducing the diagnostic cost per patient.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
15
Inclusion Criteria
  • Diagnosis of epileptic encephalopathy, defined by the clinical association of epilepsy and a significant delay in acquisition
  • Family case with recurrence in siblings, suggesting autosomal recessive transmission or X-linked inheritance (with or without parental consanguinity), or sporadic case resulting from inbreeding.
  • Lack of etiologic orientation based on clinical examination.
  • Normal routine diagnostic genetic examinations including a metabolic check-up, array CGH analysis.
  • Brain imaging which does not suggest an acquired cause.
Exclusion Criteria
  • Unavailable parental samples
  • Diagnostic orientation from one of the tests mentioned above
  • Brain imaging suggesting anoxia sequelae

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of diagnoses performed with high throughput ESThrough study completion, an average of 1 year.
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Chu Dijon Bourogne

🇫🇷

Dijon, France

© Copyright 2025. All Rights Reserved by MedPath